Videos

Latasha Jordan discusses her experience in a clinical trial with sacituzumab govitecan and comments on the side effects she experienced as well as the overall impact on her quality of life.

An expert oncologist highlights the importance of discussing clinical trial options with patients and comments on the recent FDA approval of sacituzumab govitecan in triple-negative breast cancer based on the ASCENT 3 trial.

A patient with triple-negative breast cancer, Latasha Jordan, reflects on the mental and emotional challenges she faced when she learned of her disease progression and shares her positive experience with physician referral thereafter.

A leader in breast oncology and a triple-negative breast cancer survivor discuss the role of active surveillance for post-surgical disease progression and emphasize the importance of support from health care providers after recurrence.

Aditya Bardia, M.D., MPH, and triple-negative breast cancer survivor, Latasha Jordan, discuss the importance of shared decision-making when considering mastectomy or lumpectomy and radiation for triple-negative breast cancer.

Latasha Jordan discusses her experience with neoadjuvant chemotherapy, and an expert in the management of breast cancer, Aditya Bardia, M.D., MPH, reviews common side events associated with systemic treatment.

Mel Mann, the longest living person who participated in the clinical trial for Gleevec – which was approved by the FDA just over 20 years ago – shares what he would tell his younger self.

Liposarcoma survivor Arianne Missimer discusses the training process for ‘American Ninja Warrior’ and how she felt the day of competition.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

More people are aware of the disparities LGBTQ patients face, but prohibitive legislature could be moving the needle backward when it comes to equality in care.

A survivor shares how she chose to approach her mindset during cancer treatments to keep herself from spiraling.

View the full CURE Educated Patient Leukemia Summit on demand.

A survivor of osteosarcoma who underwent treatment in the 1960s in a segregated hospital ward, shares how he was able to find strength during that time.

CURE spoke with Dr. Rajiit Rampal, on behalf of the MPN Research Foundation, about MPN symptoms and their management.

CURE spoke with Brandon Goetzman, board member from the MPN Research Foundation, on elevating the patient’s voice when it comes to their care for myeloproliferative neoplasms.

CURE spoke with Dr. Gabriela Hobbs, on behalf of the MPN Research Foundation, about the need for clinical trial education for patients with myeloproliferative neoplasms.

CURE spoke with Dr. Rajiit Rampal, on behalf of the MPN Research Foundation, about disease progression in myeloproliferative neoplasms.

CURE spoke with Dr. Gabriela Hobbs, on behalf of the MPN Research Foundation, about currently available treatment options, as well as those under clinical investigation, for patients with myeloproliferative neoplasms.

Rob Paulsen is the voice behind many beloved cartoon characters, but after receiving a cancer diagnosis, he discovered a whole new way to relate to others.

Online resources available to patients with lung or thyroid cancer who are considering participation in a clinical trial after undergoing comprehensive genomic profiling.

The pros and cons of conducting pathology assessments for comprehensive biomarker tests in central laboratories versus local laboratories.

Dr Thomas E. Hutson comments on the rationale for using combination immune therapy, as well as a combination of immune therapy and an oral VEGF inhibitor for initial treatment of RCC.

Kidney cancer expert, Dr Thomas E. Hutson, shares insight on managing adverse events resulting from combination therapy in RCC.

An expert discusses the most common reasons his patients ask him about medical marijuana.

Current barriers that impact patient access to comprehensive biomarker testing in the community and efforts underway to help advocate for increased accessibility to molecular assays moving forward.

Resources available to support patients and community oncologists who are interested in learning more and gaining access to comprehensive biomarker testing.

The vaccine immune response monitoring platform can identify weak responses in patients with cancer and help determine the potential need for a booster shot.

Thomas E. Hutson, DO, PharmD, discusses his approach to determining the optimal initial therapy for a patient with RCC.